HOME >> BIOLOGY >> NEWS
JCI Table of Contents, November 3, 2003

R> Phone: 215-573-2955
Fax: 215-573-7599
E-mail: tlaufer@mail.med.upenn.edu

View the PDF of this article at: https://www.the-jci.org/press/18310.pdf

**********************************************

ARNT mice controlling skin function?

Junji Takeda and colleagues from Osaka University and the National Cancer Institute reveal that the aryl hydrocarbon receptor nuclear translocator (ARNT) affects the structure of ceramides in the skin and disrupts the function of the epidermal barrier, which protects against foreign environmental stimuli and injury. These findings are reported in the November 3 issue of the Journal of Clinical Investigation.

ARNT, a transcription factor of the Per/AHR/ARNT/Sim family, regulates gene expression in response to environmental stimuli such as xenobiotics and hypoxia. To examine its role in the epidermis, Takeda and colleagues disrupted Arnt in keratinocytes. While the architecture of the stratum corneum in Arnt/ mice was found to be similar to that in control mice, the permeability barrier function and the composition of ceramides were significantly different. In particular, 4-desaturated and 4-hydroxylated ceramide species were diminished in the Arnt/ mice, whereas 4-saturated ceramides were elevated.

These data suggest that ARNT regulates ceramide biosynthesis through 4-desaturation and that maintenance of ceramide composition is important in epithelial barrier function.

TITLE: Alteration of the 4-sphingenine scaffolds of ceramides in keratinocyte-specific Arnt-deficient mice affects skin barrier function

AUTHOR CONTACT:
Junji Takeda
Osaka University Graduate School of Medicine, Osaka, Japan.
Phone: 81-6-6879-3262
Fax: 81-6-6879-3266
E-mail: takeda@mr-en
'"/>


Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
3-Nov-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, 1 October, 2003
4. JCI Table of Contents, September 15, 2003
5. JCI Table of Contents
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI Table Contents November

(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/27/2014)... Cancer Institute have found that targeting a molecule in ... according to research published in Nature today ... Queen Mary University of London, have found that a ... to repair itself after chemotherapy or radiotherapy, which kill ... FAK from blood vessels that grew in melanoma or ...
(Date:7/27/2014)... data from over 18,000 patients, scientists have identified ... in Parkinson,s disease, including six that had not ... Nature Genetics , was partially funded by the ... scientists working in NIH laboratories. , "Unraveling the ... the multiple mechanisms involved in this complex disease, ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Calif. , July 24, 2014  Asterias ... in the emerging field of regenerative medicine, announced ... of a presentation to investors on Tuesday, July ... PDT.  The presentation will include an overview of ... access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
Cached News: